For companies considering a divestment, minority investment, or strategic sale in Life Sciences and Healthcare, rigorous vendor due diligence is essential to maximize value and ensure a smooth transaction. Buyers expect transparency, consistency, and a credible articulation of the company’s commercial performance, growth potential, and risk profile. Without a structured vendor DD, sellers risk prolonged negotiations, valuation pressure, or loss of control over the transaction narrative.
We are particularly recognized for supporting mid-size and family-owned companies in Life Sciences and Healthcare as they prepare for a transaction. In these contexts, vendor due diligence goes beyond a technical exercise: it is a strategic process conducted hand-in-hand with management teams to clarify positioning, sharpen the equity story, and define realistic growth trajectories. Our work helps leadership teams step back, assess strategic options, and align on the development priorities of the business — whether the objective is a full sale, a partial opening of capital, or preparation for the next growth phase.
Our vendor DD approach delivers a clear, credible, and investor-ready view of the business, covering market attractiveness, competitive positioning, customer and payer dynamics, pricing logic, regulatory exposure, and scalability. We support companies across pharmaceuticals, MedTech, diagnostics, Consumer Health, pharma services (CROs, CDMOs), and healthcare services such as pharmacy networks or care delivery platforms. In parallel, we help structure data rooms, prepare management presentations, and anticipate key buyer questions to ensure consistency throughout the process.We are well known and trusted by private equity funds active in Life Sciences and Healthcare, and our vendor due diligence work is designed to meet investor expectations while preserving credibility and momentum. By combining strategic insight, rigorous analysis, and close collaboration with management, we help sellers optimize valuation, reduce execution risk, and enter transactions with clarity, confidence, and a compelling strategic narrative.
